Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health, Inc. (NYSE: TDOC) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed insight into its virtual care business, financial condition and governance. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe material events, segment performance and capital structure decisions.
Recent Form 8-K filings for Teladoc Health have addressed topics such as quarterly financial results, preliminary earnings announcements, entry into a senior secured revolving credit facility, amendments to the company’s 2023 Employment Inducement Incentive Award Plan, and changes in executive leadership and Board composition. For example, the company has reported on its second and third quarter 2025 results, including revenue by type and geography, Integrated Care and BetterHelp segment performance, and adjusted EBITDA. It has also disclosed the establishment of a five-year revolving credit facility and amendments to its inducement equity plan to increase the number of shares reserved for issuance.
On this page, investors can review Teladoc Health’s SEC filings to understand how the company reports revenue from access fees and other sources, how it presents non-GAAP measures such as adjusted EBITDA, and how it describes its capital allocation priorities. Filings also provide information on leadership transitions, director decisions, and compensatory arrangements, including inducement awards of restricted stock units and performance stock units.
Stock Titan enhances access to these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports and 8-K current reports. Users can quickly see highlights related to Teladoc Health’s Integrated Care and BetterHelp segments, credit agreements, equity plans, and governance changes, while still being able to open the full SEC documents for complete details.
Teladoc Health is asking stockholders to vote at its 2026 virtual annual meeting on three main items: electing nine directors, an advisory Say‑on‑Pay vote on executive compensation, and ratifying Ernst & Young LLP as independent auditor for 2026. Only holders of record on March 26, 2026 may vote.
The Board is 89% independent, led by a separate independent chair, and operates through five committees, including Audit, Compensation, Nominating and Corporate Governance, and Quality of Care and Patient Safety. Two new independent directors joined in 2026, bringing average director tenure to six years and average age to 67.
For 2025, Teladoc reported $2.5 billion in total revenue, $281 million in adjusted EBITDA with an 11.1% margin, $781 million in cash and cash equivalents, and $458 million in international revenue, which grew 12%. Executive pay is highly performance‑based: equity and incentives represented 92.9% of the CEO’s target compensation and 83.7% for other named executives, and lower‑than‑target results led to below‑target payouts. The Board recommends voting FOR all management proposals.
Teladoc Health Chief Accounting Officer Joseph Ronald Catapano reported routine equity compensation activity and a small related share sale. On April 1, 2026, restricted stock units converted into 2,083 shares of Teladoc common stock on a one-for-one basis at a conversion price of $0.00.
On April 2, 2026, he sold 675 common shares at $5.114 per share solely to cover the tax withholding obligation tied to the RSU vesting, rather than as a discretionary open-market sale. After these transactions, he directly held 10,249 common shares.
The filing notes that on October 1, 2024, he was granted 25,000 restricted stock units, with one-third vesting on the first anniversary of the grant and the remainder vesting in eight substantially equal quarterly installments thereafter.
SALKA SUSAN R reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Susan R. Salka received a grant of 48,638 restricted stock units (RSUs) linked to Teladoc common stock. Each RSU represents a contingent right to receive one share of common stock. One-third of the RSUs vest on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter. Following this award, Salka directly holds 48,638 RSUs reported in this filing.
Teladoc Health, Inc. director Susan R. Salka filed an initial Form 3 ownership report. The filing lists her as a director but shows no reportable share transactions or derivative positions, serving mainly as a baseline disclosure of insider status and potential future reporting obligations.
Teladoc Health, Inc. expanded its board of directors to nine members and appointed Susan R. Salka as a new director, effective March 30, 2026. She will serve on the board’s audit and compensation committees, and has been designated an independent director and an “audit committee financial expert.” Ms. Salka is the former president and CEO of AMN Healthcare Services, where over a 33‑year tenure she helped drive 26 acquisitions and grow revenue to over $5 billion. She also brings prior board experience at several major healthcare and life sciences companies.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A reporting on holdings of Teladoc Health Inc. The filing states amount beneficially owned: 0 and percent of class: 0%, reflecting an internal realignment where certain Vanguard subsidiaries now report separately in reliance on SEC Release No. 34-39538 (January 12, 1998). The filing lists Vanguard's address and certifies that no other single person holds more than 5% of the class. The form is signed by Ashley Grim on 03/27/2026.
Teladoc Health, Inc. President, U.S. Group Health, Kelly Bliss reported compensation-related equity activity involving performance stock units tied to common stock. On 2026-02-27, she was granted 15,596 performance stock units, each representing a contingent right to receive one share of TDOC common stock.
The award size was determined using metrics based on Teladoc’s 2025 financial results, and the units vest one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments. The filing also records the exercise or conversion of 5,198 performance stock units into common stock and amends a prior Form 4 to correct the originally reported number of units awarded.
Teladoc Health, Inc. reported insider activity by CEO Charles DiVita III involving equity awards, vesting, and related tax sales. On March 10, 2026, restricted stock units and performance stock units converted one-for-one into a total of 64,653 shares of common stock. He was also awarded 43,703 performance stock units, with vesting tied to the company’s 2025 financial results and a schedule that began March 10, 2026. On March 11, 2026, 27,731 shares of common stock were sold at $5.49 per share to cover tax withholding obligations related to these vestings. After these transactions, DiVita directly owned 364,784 shares of Teladoc common stock.
TDOC affiliate files Form 144 reporting proposed and recent sales of common stock.
The filing lists 27,731 restricted shares tied to vesting on 03/10/2026 as securities to be sold. It also records dispositions by Charles Divita of 17,138 shares on 12/11/2025 and 50,145 shares on 03/02/2026.